A Clinical Study for

Kids and Adults with Eczema

ADORING is a phase 3 clinical study evaluating an investigational non-steroidal topical cream for people aged 2 years and older who suffer from moderate to severe eczema (also known as atopic dermatitis or AD).

Am I Eligible?

Share ADORING with your doctor

 
 
 

A Clinical Study for

Kids and Adults with Eczema

ADORING is a phase 3 clinical study evaluating an investigational non-steroidal topical cream for people aged 2 years and older who suffer from moderate to severe eczema (also known as atopic dermatitis or AD).

Am I Eligible?

Share ADORING with your doctor

 

About the ADORING study

ADORING is a phase 3 clinical study evaluating the safety and efficacy of tapinarof cream, 1% for the topical treatment of moderate to severe eczema in adults and children aged 2 years and above.

The study is an eight-week double-blind study in which participants will be randomized (chosen by chance) to receive tapinarof cream, 1% or a vehicle cream (the same cream but without tapinarof in it) to be applied once daily to areas of the skin suffering from moderate to severe eczema. Double-blind means that during the study, neither you nor your study doctor will know if you are receiving tapinarof cream or the vehicle cream.

Although several treatment options are available to treat eczema, we are evaluating tapinarof for application to large areas of the body for long periods of time. Tapinarof is an investigational non-steroidal product that is being evaluated to determine if it may help control eczema signs and symptoms.

If you choose to take part in this study, you will be one of approximately 400 adults and children aged 2 years and above who will be enrolled across approximately 60 sites in the US and Canada.

adults and children
sites across the US and Canada
macbook

All eligible study participants will receive (at no cost):

Study-related consultation and care

Study visits, tests, assessments, and procedures

Study treatment or vehicle cream

To learn more and to see if you or your child may be eligible to participate in the ADORING study, take our brief online questionnaire.

Am I Eligible?

Who may be eligible? Participants in the ADORING study must meet the following criteria:* *Other criteria will apply

image blog

Male or female, 2 years of age or older

image blog

Have eczema that covers between 5% and 35% of their body, not including the scalp

NOTE: Participants with eczema only on their palms and soles are not eligible.

image blog

Been diagnosed with eczema for at least 6 months for those 6 years old and above or 3 months for those 2 to 5 years old

The Investigational Drug Tapinarof is a therapeutic aryl hydrocarbon receptor modulating agent (TAMA) that has been shown to activate certain receptors in multiple cell types, including skin cells. Tapinarof targets specific cells, and it works differently than steroidal eczema treatments.

non-steroidal & anti-inflammatory Tapinarof cream, 1% is an investigational non-steroidal, anti-inflammatory agent being studied for the topical (on the skin) treatment of eczema.

has been studied Tapinarof cream has been studied for use in clinical studies before, including being used up to twice daily in adults and adolescents with eczema.

deserves further study The results of those studies indicate that tapinarof cream, 1% deserves further study to determine if it is a safe and effective treatment for large areas of the skin impacted by eczema.

About Eczema

Eczema, also known as atopic dermatitis (AD), is an incurable, chronic condition that results in itchy, red, swollen, and cracked skin.1,2

Up to 30% of
children may be
affected by eczema
at some point.
Between 2% to
10% of adults
currently live with
eczema.

1. Bieber T. Atopic dermatitis. New England Journal of Medicine. 2008;358(14):1483-1494.
2. Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. Journal of the American Academy of Dermatology. 2014;70(2):338-351.

Although eczema is not contagious, it is a long-lasting and itchy inflammatory skin disease that impacts both the physical and psychological quality of life for the people who suffer from it.

Am I Eligible?
Am I Eligible?